1、GILEADSCIENCESANNOUNCESSECONDQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$6.9billionBiktarvySalesIncreased9%Year-Over-Yearto$3.5billionFosterCity,CA,August7,2025-GileadSciences,Inc.(Nasdaq:GILD)announcedtodayitssecondquarter2025resultsofoperations.“Thiswasaverys

2、uccessfulsecondquarterforGilead,includingtheFDAapprovalforYeztugoastheworldsfirsttwice-yearlyHIVpreventionoption,”saidDanielODay,GileadsChairmanandChiefExecutiveOfficer.“OurstronggrowththisquarterwasdrivenbyBiktarvy,Descovy,TrodelvyandLivdelzi,reflectingthediversityofourportfolio.Asweenterthethirdqu

3、arter,weareincreasingrevenueandearningsguidancefortheyear,andlookforwardtodeliveringcontinuedinnovationandgrowthacrossourcoretherapeuticareas.”SecondQuarter2025FinancialResultsTotalsecondquarter2025revenueincreased2%to$7.1billioncomparedtothesameperiodin2024,drivenbyhigherHIV,Livdelzi(seladelpar)and

4、Trodelvy(sacituzumabgovitecan-hziy)sales,partiallyoffsetbylowerchronichepatitisCvirus(“HCV”)andVeklury(remdesivir)sales.Dilutedearningspershare(“EPS”)was$1.56inthesecondquarter2025comparedto$1.29inthesameperiodin2024.Theincreasewasprimarilydrivenbynetunrealizedgainsonsecuritiescomparedtonetunrealize

5、dlossesin2024andhigherproductsales,partiallyoffsetbyapre-taxin-processresearchanddevelopment(“IPR&D”)impairmentchargeof$190millionrelatedtoassetsacquiredaspartoftheMYRGmbH(“MYR”)acquisitionandhigherresearchanddevelopment(“R&D”)expenses.Non-GAAPdilutedEPSof$2.01inthesecondquarter2025remainedflatcompa

6、redtothesameperiodin2024,withhigherproductsalesoffsetbyhigherR&Dexpenses.AsofJune30,2025,Gileadhad$7.1billionofcash,cashequivalentsandmarketabledebtsecuritiescomparedto$10.0billionasofDecember31,2024.Duringthesecondquarter2025,Gileadgenerated$827millioninoperatingcashflow,netofafinal$1.3billiontrans